| Methods |
2‐ to 3‐week screening/washout period; 4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 95‐114 mm Hg; 12‐week double‐blind treatment |
| Participants |
Telmisartan 40 mg: n=72(50 males,22 females); mean age=54.6(12.0) years; baseline supine SBP=155.2(14.3) mm Hg, DBP=100.8(4.3) mm Hg;
Telmisartan 80 mg: n=72(41 males,31 females); mean age=54.4(10.4) years; baseline supine SBP=153.7(13.0) mm Hg, DBP=100.0(3.6) mm Hg;
Telmisartan 120 mg: n=73(48 males,25 females); mean age=53.2(11.0) years; baseline supine SBP=151.9(10.4) mm Hg, DBP=100.2(4.0) mm Hg;
Telmisartan 160 mg: n=75(51 males,24 females); mean age=53.4(10.5) years; baseline supine SBP=154.2(14.6) mm Hg, DBP=100.5(4.9) mm Hg;
Placebo: n=76(49 males,27 females); mean age=55.6(9.6) years; baseline supine SBP=154.8(11.8) mm Hg, DBP=100.4(4.5) mm Hg |
| Interventions |
Telmisartan 40 mg once daily;
Telmisartan 80 mg once daily;
Telmisartan 120 mg once daily;
Telmisartan 160 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported; endpoint BP and SD not reported; calculated SD of change from N and SE of change; change in BP data from Figures 1 and 2, p. 235; SE of change data from Table 2, p. 234; Jadad score=3; funding source= Boehringer Ingelheim Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
